Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
International Society for Disease Surveillance biosurveillance. Every year, the ISDS conference draws over 350 professionals from a broad range of disciplines to learn the latest achievements, analytic methods, best practices, conceptual frameworks, and technical innovations in the rapidly evolving field of disease surveillance. The ISDS conferences provide fertile ground for cultivating new ideas and partnerships by bringing together local, state, and federal public health practitioners, academic researchers, clinicians, policymakers, and decision makers from governmental and nongovernmental entities. The 12th annual conference was held in December 2013, in New Orleans, LA. The theme for the 2013 conference—Translating Research and Surveillance into Action—highlighted one of the salient